Amit Mahipal

University Hospitals Seidman Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (28)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (9)

Udhayvir Singh Grewal

UNITED STATES

View details

Ankit Mangla

University of South Florida

UNITED STATES

View details

Christopher Lieu

Associate Professor

University of Denver

UNITED STATES

View details

Patrick Starlinger

Medical University of Vienna

AUSTRIA

View details

Thomas J George

University of Florida

UNITED STATES

View details

Thorvardur Halfdanarson

Professor of Oncology

Mayo Clinic

UNITED STATES

View details

Sakti Chakrabarti

University Hospitals Seidman Cancer Center

UNITED STATES

View details

Nguyen H Tran

Consultant/Assistant Professor

Mayo Clinic

UNITED STATES

View details

Christopher W. Towe

University Hospitals Cleveland Medical Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Amit Mahipal

Research Interests

Explore related searches

Contact this professor

Articles (28)

Genomic Landscapes of Early-Onset Versus Average-Onset Colorectal Cancer Populations

Toxicity Associated with Pembrolizumab Monotherapy in Patients with Gastrointestinal Cancers: A Systematic Review of Clinical Trials

Safety and Efficacy of Anti–Human Epidermal Growth Factor 2 Agents in the Treatment of Biliary Tract Cancers: A Systematic Review

Real-World Tolerability of Capecitabine and Oxaliplatin in Patients in the United States With Localized Colorectal Cancer Undergoing Curative-Intent Treatment

Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Carcinoma

Frequency and outcomes of BRAF alterations identified by liquid biopsy in metastatic, non-colorectal gastrointestinal cancers

SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study

Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study

Outcome of Patients with Locally Advanced Rectal Cancer Pursuing Non-Surgical Strategy in National Cancer Database

Circulating Tumor DNA Predicts Early Recurrence following Locoregional Therapy for Oligometastatic Colorectal Cancer

HER2-directed therapy following ctDNA-identified ERBB2 amplification in patients with advanced gastroesophageal cancer: exploration of real-world outcomes

Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma

Frequency of Common and Uncommon BRAF Alterations among Colorectal and Non-Colorectal Gastrointestinal Malignancies

Evaluating the Therapeutic Potential of Durvalumab in Adults with Locally Advanced or Metastatic Biliary Tract Cancer: Evidence to Date

Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer

Adoption of Total Neoadjuvant Therapy in the Treatment of Locally Advanced Rectal Cancer

FOxTROT Study Results: Some Burning Questions Need Answers

Differences in the surgical management of early-stage hepatocellular carcinoma at minority versus non-minority-serving hospitals

Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience

Outcome of Patients With Early-Stage Mismatch Repair Deficient Colorectal Cancer Receiving Neoadjuvant Immunotherapy: A Systematic Review

FOxTROT Study Results: Some Burning Questions Need Answers

Disparities in guideline-compliant care for patients with pancreatic ductal adenocarcinoma at minority-versus non-minority-serving hospitals

Circulating Tumor DNA-Guided Recurrence Risk Assessment in Esophageal and Gastric Cancer: Assay Holds the Key

Circulating tumor DNA-guided minimal residual disease assessment in colorectal cancer

Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma

Economic Cost and Sustainability of Oral Therapies in Precision Oncology

Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)—Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)

Collaborators (9)

Udhayvir Singh Grewal

Ankit Mangla

Christopher Lieu

Patrick Starlinger

Thomas J George

Thorvardur Halfdanarson

Sakti Chakrabarti

Nguyen H Tran

Christopher W. Towe

Make your next move.